Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a critical study evaluating the efficacy of resmetirom in patients with compensated NASH …
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) showcased new findings from its pivotal Phase 3 RAISE trial at the Neurocritical Care Society Annual Meeting, highlighting the potential of intravenous …
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status Epilepticus Read More
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of its RSV vaccine, AREXVY, over three full RSV …
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons Read More
WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. The trial demonstrated …
AstraZeneca’s AIRSUPRA Proven Effective in Reducing Severe Asthma Attacks Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of its SEISMiC Phase 2b trial design by the European Society of Cardiology Heart Failure. The trial is exploring …
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment Read More
BERWYN, PA — Panavance Therapeutics Inc. announced interim results from its Phase 1 clinical trial at the 2024 Visceral Medicine Congress in Leipzig, Germany. The study evaluates the safety and efficacy …
Panavance Unveils Game-Changing Data: A New Hope for Pancreatic Cancer Patients? Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a pivotal development as the FDA lifted the clinical hold on its investigational drug application for OCU200.
FDA Greenlights Ocugen’s Revolutionary Eye Treatment: What It Means for Vision Care Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced promising topline results from its Phase 1 study of tivoxavir marboxil, an investigational one-dose influenza treatment. Designed to inhibit the CAP-dependent …
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil Read More
WAYNE, PA — Palvella Therapeutics, Inc. has been awarded up to $2.6 million by the FDA’s Office of Orphan Products Development to support its Phase 3 SELVA trial. This trial investigates …
Palvella Therapeutics Secures $2.6 Million FDA Grant for Phase 3 Trial Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More